PubMed Health⌕ Search

Biomedical subjects

F Casellas

Publications and source records attributed to F Casellas.

69 records · Page 4Linked to original sources
PubMed1986

Intestinal permeability to 99mTc-diethylenetriaminopentaacetic acid in inflammatory bowel disease.

Intestinal permeability in inflammatory bowel disease and its relation to periods of disease activity has been investigated by measuring the urinary excretion of DTPA labeled with 99mTc. Urine excretion in 10 control subjects was 2.7 +/- 1% of the test dose. Twelve patients with ulcerative colitis excreted 5.08 +/- 1.6% in remission, 10.61 +/- 2% during periods of mild activity, 19.41 +/- 0.9% during moderate activity, and 15.41 +/- 6.3% with severe activity. Sixteen patients with Crohn's disease excreted 5.7 +/- 1.9% in remission, 8.47 +/- 2.8% during mild activity of the disease, and 14.29 +/- 5.8% during moderate activity. No differences were observed between ulcerative colitis and Crohn's disease, or between ileal and colonic forms of Crohn's disease. Excretion in remission was significantly greater than in control subjects and there was a correlation between excretion and disease activity. In serial determinations done in seven patients we found that urine excretion of the test substance correlated with disease activity. We also studied DTPA excretion in 10 cases with gastric or duodenal ulcer (2.28 +/- 1.4%), six cases of acute gastroenteritis (4.87 +/- 3.1%) and nine cases with other intestinal diseases (3.6 +/- 1.1%). In all these cases, DTPA excretion was lower than in inflammatory bowel disease. Our results show that the urinary excretion of DTPA is a simple test that measures accurately the degree of activity of inflammatory bowel disease. The test is useful in Crohn's disease as well as in ulcerative colitis, and detects intestinal permeability abnormalities even in clinical remission. Significantly lower excretions are found in other intestinal diseases. The test may be recommended as a screening test for use in clinical practice.

Adolescent↗
PubMedDate not supplied

Influence of the substrate on the reproducibility of the hydrogen breath test to measure the orocecal transit time.

BACKGROUND: The H2 breath test is widely used for the measurement of the orocecal transit time (OCTT). However, its clinical applicability is limited by its suboptimal reproducibility. AIM: To investigate whether changes in the substrate for the H2 breath test improve its reliability for the measurement of the OCTT. METHODS: 72 consecutive patients referred for measurement of the OCTT were studied. The breath test was performed twice, on consecutive days. One group of patients ('lactulose + water' group) received lactulose 13.3 g in water both days. Another group ('lactulose + diet') received lactulose 13.3 g in a liquid meal of 400 kcal. A third group ('lactulose-lactitol') received 13.2 g of lactulose the first day and 10 g lactitol the following day. The fourth group ('lactitol + water') received lactitol 10 g in water both days. Alveolar breath was sampled every 10 min for the next 3 h for H2 chromatography. RESULTS: OCTT in the first and second day test for the groups 'lactulose + water', 'lactulose + diet' and 'lactitol + water' were similar. In these three groups, the values obtained on the first and second day did not differ from 0 and were also significantly correlated. However, the correlation and the mean coefficient of variation were better in group 'lactulose + water' than in the groups 'lactulose + diet' and 'lactitol + water'. In group 'lactulose-lactitol' the results on both days were significantly correlated although the delta between matched values was different from 0 (p = 0.03). CONCLUSION: The meal substrate influences the variability of the OCTT. However, reproducibility of the test does not improve with the addition of a liquid meal.

Administration, Oral↗
PubMedDate not supplied

Practicality of 5-aminosalicylic suppositories for long-term treatment of inactive distal ulcerative colitis.

BACKGROUND/AIMS: Topical 5-aminosalicylic acid (5-ASA) is regarded as an effective form of therapy for distal ulcerative colitis. Unfortunately, experience about acceptability and tolerance of long-term treatment with 5-ASA suppositories is still meager. METHODOLOGY: We have evaluated the performance of 5-ASA suppositories as maintenance treatment in 34 patients with inactive distal colitis. Prior to entering the study, all patients were in clinical remission for 1-12 months. A single 500 mg 5-ASA suppository was administered nightly for 12 months in every patient and all other treatments were discontinued. Clinical evaluation was performed at 3, 6 and 12 months. RESULTS: Four patients withdrew from the study within the first 3 months because of local intolerance to the suppositories. Score of both comfort and tolerance was significantly higher in patients who continued treatment than in those who withdrew. Two patients who stayed in remission withdrew, one at 7 months because of thrombocytopenia and the other at 9 months for personal reasons. Of the 28 remaining patients, 7 relapsed and 21 remained in clinical remission at the end of the 12-month study period. Eleven of the 21 responder patients agreed to a sigmoidoscopic examination, that confirmed remission in all of them. Eight out of the 9 patients who had previously received 5-ASA enemas preferred suppositories to enemas. Apart from the 4 patients who did not tolerate suppositories, 26 patients considered this form of therapy quite comfortable. CONCLUSIONS: 5-ASA suppositories are generally well tolerated and considered comfortable for treatments of at least one year.

Adolescent↗